Looking for a new broker?
GT Biopharma, Inc. stock is down -6.25% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36% of the previous 49 December’s closed higher than November.
GT Biopharma, Inc. focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate, is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company was formerly known as OXIS International, Inc
